 |
Home | Terms of Use | Privacy Statement | Contact Us |
 |
|
||||||
 |
|
||||||||
 |
||||
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
| Kepivance® is indicated to decrease the incidence and duration of
severe oral mucositis in patients with hematologic malignancies
receiving myelotoxic therapy requiring hematopoietic stem cell
support. The safety and efficacy of Kepivance® have not been
established in patients with non-hematologic malignancies.
Important Safety Information In patients with hematologic malignancies, the most common serious adverse reaction in clinical trials attributed to Kepivance® was skin rash reported in less than 1% of patients. |
|||||||||||
|
|||||||||||
|
|
|
|||||||||
